Section Arrow
RNXT.NASDAQ
- RenovoRx
Quotes are at least 15-min delayed:2024/10/31 20:46 EDT
Last
 0.998
-0.002 (-0.20%)
Day High 
Prev. Close
1-M High
1.11 
Volume 
26.47K 
Bid
0.99
Ask
1.02
Day Low
0.9 
Open
1-M Low
0.7736 
Market Cap 
23.99M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 0.98 
20-SMA
50-SMA 1.02 
52-W High 2.35 
52-W Low 0.5306 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.60/-0.41
Enterprise Value
24.01M
Balance Sheet
Book Value Per Share
0.39
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ELABElevai Labs0.059-0.0339-36.49%-- 
AVTEAerovate Therapeutics2.46+0.27+12.33%-- 
ENSCEnsysce Biosciences0.5754-0.0629-9.85%-- 
TNXPTonix Pharmaceuticals Holding Corp.0.1445-0.0099-6.41%-- 
GLYCGlycoMimetics0.4069-0.0496-10.87%-- 
Quotes are at least 15-min delayed:2024/10/31 20:46 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.